Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine (Q39450022)

12 September 2017

title

Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine (English)

1 reference

12 September 2017

1 reference

Takeo Shimasaki

1

1 reference

12 September 2017

Yasuhito Ishigaki

2

1 reference

12 September 2017

Yuka Nakamura

3

1 reference

12 September 2017

Takanobu Takata

4

1 reference

12 September 2017

Naoki Nakaya

5

1 reference

12 September 2017

Hideo Nakajima

6

1 reference

12 September 2017

Itaru Sato

7

1 reference

12 September 2017

Xia Zhao

8

1 reference

12 September 2017

Ayako Kitano

9

1 reference

12 September 2017

Kazuyuki Kawakami

10

1 reference

12 September 2017

Takuji Tanaka

11

1 reference

12 September 2017

Tsutomu Takegami

12

1 reference

12 September 2017

Naohisa Tomosugi

13

1 reference

12 September 2017

Toshinari Minamoto

14

1 reference

12 September 2017

Yoshiharu Motoo

15

1 reference

12 September 2017

publication date

1 November 2011

1 reference

Journal of Gastroenterology

12 September 2017

published in

1 reference

12 September 2017

volume

47

1 reference

12 September 2017

issue

3

1 reference

12 September 2017

page(s)

321-333

1 reference

12 September 2017

cites work

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

Global cancer statistics, 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

Systemic chemotherapy for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

Pancreatic cancer: basic and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

Pancreatic cancer biology and genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

A review of kinases implicated in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

The glamour and gloom of glycogen synthase kinase-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

GSK-3: tricks of the trade for a multi-tasking kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

Regulation of GSK-3: a cellular multiprocessor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

GSK3 inhibitors: development and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

Pharmacological inhibitors of glycogen synthase kinase 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

Inhibition of GSK-3 beta activity attenuates proliferation of human colon cancer cells in rodents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

Potential therapeutic effect of glycogen synthase kinase 3beta inhibition against human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

Deregulated GSK3{beta} sustains gastrointestinal cancer cells survival by modulating human telomerase reverse transcriptase and telomerase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

An emerging strategy for cancer treatment targeting aberrant glycogen synthase kinase 3 beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

Maintenance of constitutive IkappaB kinase activity by glycogen synthase kinase-3alpha/beta in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

Associations Among -TrCP, an E3 Ubiquitin Ligase Receptor, -Catenin, and NF- B in Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

Detection of active fraction of glycogen synthase kinase 3beta in cancer cells by nonradioisotopic in vitro kinase assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

Effect of gemcitabine on the expression of apoptosis-related genes in human pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

The role of nuclear factor kappaB in pancreatic cancer and the clinical applications of targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

New aspects of regulatory signaling pathways and novel therapies in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

Apoptotic pathways in pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

Tumor protein 53-induced nuclear protein 1 is a major mediator of p53 antioxidant function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

Molecular and functional characterization of the stress-induced protein (SIP) gene and its two transcripts generated by alternative splicing. SIP induced by stress and promotes cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

The retinoblastoma tumour suppressor in development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

Clinical significance of dihydropyrimidine dehydrogenase and thymidylate synthase expression in patients with pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0484-9

Role of glycogen synthase kinase-3 in TNF-alpha-induced NF-kappaB activation and apoptosis in hepatocytes

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22041920

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Progression model for pancreatic cancer.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22041920

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22041920

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00535-011-0484-9

1 reference

12 September 2017

1 reference